Seeking Alpha

Shares of OxiGene (OXGN +31%) are soaring today after the company released results from its...

Shares of OxiGene (OXGN +31%) are soaring today after the company released results from its Phase 2 trial of Zybrestat, a potential treatment for patients with polypoidal choroidal vasculopathy, a degenerative eye disease with features similar to age-related macular degeneration. The data was presented today at the annual meeting of the American Academy of Ophthalmology.
Comments (1)
  • smokeyRose
    , contributor
    Comments (78) | Send Message
     
    Bought this stock years ago for $2.00 went up to $20.00!!! :)
    Bought it again today for 0.41 lets Hope for a Deja vu
    13 Nov 2012, 07:26 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs